EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

ANCA-associated vasculitis—treatment standard

Aglaia Chalkia iD, David Jayne

Nephrology Dialysis Transplantation · 31.05.2024 · 39 (6) · 944-955

DOI: 10.1093/ndt/gfad237 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 08.11.2023. Verfasst von Aglaia Chalkia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Immunosuppressive Agents. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Cambridge, Stavros Niarchos Foundation, National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are characterized by small-vessel necrotizing inflammation, and prior to the advent of immunosuppressive therapy frequently had a fatal outcome. Treatment has transformed AAV into a relapsing/remitting disease with increased drug-related toxicities and organ damage. The use of glucocorticoids, cyclophosphamide and immunosuppressives (including azathioprine, mycophenolate and methotrexate) was optimized through a sequence of clinical trials establishing a standard of care against which subsequent targeted therapies could be developed. Improved understanding of pathophysiology has supported the development of B-cell depletion and complement inhibition in granulomatosis with polyangiitis and microscopic polyangiitis, and interleukin 5 inhibition for eosinophilic granulomatosis with polyangiitis, leading to the approval of newer agents for these conditions. There has been an increased attention on minimizing the adverse effects of treatment and on understanding the epidemiology of comorbidities in AAV. This review will focus on recent evidence from clinical trials, especially with respect to glucocorticoids, avacopan, plasma exchange, rituximab and mepolizumab, and their interpretation in the 2022 management recommendations by the European League of Associations of Rheumatology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisImmunosuppressive AgentsHumansGlucocorticoidsStandard of Care

Stichwörter der Autor:innen

ANCA-associated vasculitisdiagnosispathophysiologyprognosistreatment

Substanzen

Immunosuppressive AgentsGlucocorticoids

Autor:innen und Institutionen

  • Department of Medicine, University of Cambridge, Cambridge, UK.
  • Nephrology Department, Hippokration General Hospital, Athens, Greece.

ORCID-Profile: Aglaia Chalkia

Förderung

  • University of Cambridge
  • Stavros Niarchos Foundation
  • National Institute for Health and Care Research

Zitieren

APA

Chalkia, A., & Jayne, D. (2024). ANCA-associated vasculitis—treatment standard. Nephrology Dialysis Transplantation, 39(6), 944-955. https://doi.org/10.1093/ndt/gfad237

Vancouver

Chalkia A, Jayne D. ANCA-associated vasculitis—treatment standard. Nephrology Dialysis Transplantation. 2024;39(6):944-955. doi:10.1093/ndt/gfad237

BibTeX
@article{Chalkia2024,
  author = {Chalkia, Aglaia and Jayne, David},
  title = {ANCA-associated vasculitis—treatment standard},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  volume = {39},
  number = {6},
  pages = {944--955},
  doi = {10.1093/ndt/gfad237}
}
Kostenlos starten →